Baylor Miraca Genetics Laboratories

Prenatal Chromosomal Microarray Testing

I. CMA–TARGETED

This Prenatal array is very similar to what was used in the NIH trial and is ideal for physicians, counselors and patients who want detection of all well characterized, deletion and duplication syndromes. It also includes additional deletion/duplication syndromes that were not yet characterized when the NIH array was designed. This array includes 105,000 oligonucleotides and has a very low rate of variants of unknown significance.

II. CMA-TARGETED + LIMITED KARYOTYPE ANALYSIS

This option includes the Limited array as described above plus a 5 cell chromosome analysis to rule out rearrangements not detected by microarray such as balanced translocations, inversions and triploidy. The benefits of the limited karyotype are lower cost and a quicker turnaround time.

III. CMA – EXPANDED

BMGL also offers an EXPANDED prenatal array. This array offers exon by exon coverage for over 1700 genes. In our experience, this array detects more genetic disorders, without significantly increasing the variant of unknown significance rate which can lead to difficult counseling situations. The EXPANDED array is recommended for families who want the highest level of chromosomal microanalysis possible (understanding no single test can assess for every possible genetic outcome).

IV. CMA-EXPANDED + LIMITED KARYOTYPE ANALYSIS

This option includes the Expanded array as described above, plus a 5 cell chromosome analysis to rule out rearrangements not detected by microarray such as balanced translocations, inversions and triploidy. The benefits of the limited karyotype are lower cost and a quicker turnaround time.

1. Insurance contracts with all of the major providers. This provides for the least out of pocket expense to the patient.

2. Flexible payment plans.

3. BMGL will perform prior authorization at the request of the patient, physician, or counselor.

4. Industry leading turnaround time as a product of optimizing direct amnio and CVS analysis (80% if results are reported in 5-7 calendar days).

5. BMGL custom designed arrays avoid regions of uncertainty, providing results of uncertain clinical significance in less than 1% of cases.

6. Large group of lab directors and clinicians with extraordinary experience in interpreting and signing out prenatal arrays. We have signed out more than 4000 prenatal arrays since 2007, both as clinical care leaders and as part of the NIH study.

7. Parental studies at no cost BMGL requests that blood samples on both parents be submitted together with the fetal specimen in order to improve turn-around time and reduce parental anxiety where possible.

We were a pioneer in developing and offering chromosomal microarray services, and we remain an industry leader in the implementation of new technology for this and other services. The Baylor Miraca Genetics Laboratories (BMGL) offer a variety of testing for Prenatal Chromosomal Microarray, Analysis. BMGL has been a leading provider of clinical array testing for over 10 years. Now that the National Institute of Health (NIH) Prenatal CMA trial is complete, we want to be your Prenatal CMA lab of choice. BMGL offers many advantages to help patients, physicians and counselors with CMA studies.

Baylor Miraca
Genetics Laboratories

2450 Holcombe Boulevard
Suite O-100, Houston, Texas 77021
1-800-411-GENE (4363)
713-798-6555
www.BMGL.com

9/2015